StockData
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31

Xilio Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.33−0.22 (-2.57%)

Close on Oct 19, 2026

Market cap
$161.64M
P/E (TTM)
–
Dividend yield
–

Xilio Therapeutics, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Xilio Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.